John Van Der Wielen

The state government has set up an advisory group, with executives from more than 20 businesses and community groups, to provide advice on the impacts of COVID-19 and measures to help economic recovery.

HBF achieved a net positive result in the previous financial year, despite declining investment returns contributing to a more than halving of its year-on-year profitability.

The state government has appointed the advisory council of the Future Health Research and Innovation Fund, including HBF chief executive John Van Der Wielen as chair.

Residents in WA’s north will benefit from more ambulances and paramedics as part of the first phase of the state government’s country ambulance strategy.

HBF Run for a Reason has been cancelled for a second year due to health concerns surrounding the COVID-19 pandemic.

HBF will follow through with its pledge to refund deferred claims to patients and is expecting to make about 500,000 payments worth $40 million to policyholders.

HBF's membership is set to exceed 1 million with the acquisition of CUA Health later this year.

HBF maintained profitability in the year to June, defying rising costs and recording strong investment returns to finish $17.7 million in the black.

HBF has taken a 10 per cent stake in ASX-listed dentistry outfit Pacific Smiles Group, following a 10-year partnership agreement struck between the two in 2020.

HBF’s expansion spree has rolled on apace this year, with the not-for-profit health insurer moving to acquire WA-based allied health outfit Life Ready Health Group.

John Van Der Wielen, Ivy Chen and Larry Lopez will head up a $100 million state government program launched to attract investments to potential growth industries.

John Van Der Wielen is leaving HBF after five years as managing director.

HBF’s point man on health sat down with Business News last month to talk about national expansion, the pandemic, and the pressures coming to bear on Australia’s health insurance market.

The Federal Court has cleared the way for private equity giant Blackstone Group to take over the troubled Crown Resorts business, the last major hurdle for the $8.9 billion acquisition to go ahead.

Blackstone has detailed two development opportunities at Burswood, confirmed John Van Der Wielen as its local chair and conceded governance of its casinos is a work in progress.

Len Buckeridge’s eldest son and a former union secretary are the latest additions to the commission that oversees gambling operations in WA.

Crown Resorts boss Steve McCann has stepped down after just over a year in the top job, as John Van Der Wielen is sworn in as casino licensee Burswood Limited’s new chair.

The state government has announced a challenge with a $5 million reward to solve the critical issue of healthcare delivery in the Pilbara.

Not for profits are grappling with remuneration for their directors, with one major group scaling back its payments.

John Van Der Wielen will chair Murdoch-based biotechnology company Orthocell as it prepares to scale up manufacturing with a new facility.

Crown Perth chair John Van Der Wielen has spoken bluntly about the ‘appalling’ failures of the besieged casino, but has avowed the Blackstone-owned organisation can and will be turned around.

Burns surgeon Fiona Wood has been appointed to the board of John Van Der Wielen-chaired biotechnology company Orthocell as it prepares for international commercialisation.

Former Western Australian governor Kim Beazley has joined the board of Murdoch-based biotechnology company Orthocell, chaired by John Van Der Wielen.

Mining industry executive Rebecca Tomkinson has taken on a new role as chair of the Future Health Research and Innovation Fund, replacing John Van Der Wielen.

Biotechnology company Orthocell will raise $3.5 million, with proceeds put towards its international market expansion strategy.

Having led multiple corporate transformation projects, John Van Der Wielen shares his thoughts on what works and what doesn’t.

Murdoch-based Orthocell has received regulatory approval to commence sales of Remplir in Singapore, as the listed biotech company posts a second consecutive quarter of record revenue.

Perth-based biotechnology firm Orthocell has raised $17 million to take its Remplir nerve regeneration product to the world's biggest healthcare market.

Orthocell has struck a deal with a medical equipment supply firm to distribute its nerve repair device in Singapore, sending the Perth company’s shares up 26 per cent.

Biotech firm Orthocell is a step closer to its nerve repair device Remplir being approved in the US, following the completion of its US regulatory study.

Orthocell has submitted its application for US Food and Drug Administration approval for its Remplir nerve regeneration product, marking another moment in a year full of milestones.

Murdoch-based regenerative medicine company Orthocell has posted its third consecutive quarter of record revenue, as it gears up for a final approval from the US FDA for its Remplir nerve product.

Kim Beazley-backed medtech company Orthocell has flagged an expedited expansion into several jurisdictions after strong early sales of its Remplir nerve repair technology.

Murdoch-based medtech firm Orthocell has continued its expedited expansion push, following news it had lodged an application to sell its nerve repair project Remplir in Canada.

Singapore’s Health Science Authority has granted regulatory approval for John Van Der Wielen-chaired Orthocell for use of its dental membrane project, Striate+.

Orthocell has received clearance from the US-based Food and Drug Administration to begin selling its nerve repair product Remplir in the country.

John Van Der Wielen-chaired Orthocell has received another timely boost, as it aims to further a push into Latin America.